Tasly Pharmaceutical Co.

Tianjin, China

Tasly Pharmaceutical Co.

Tianjin, China
SEARCH FILTERS
Time filter
Source Type

News Article | May 10, 2017
Site: www.businesswire.com

PARÍS--(BUSINESS WIRE)--Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), una empresa biofarmacéutica pionera de un nuevo enfoque para el desarrollo de fármacos innovadores basados en la combinación y reposicionamiento de fármacos conocidos, ha anunciado la firma de un acuerdo estratégico con Tasly Pharmaceutical (Shanghai: 600535), un grupo situado entre las 10 mejores empresas farmacéuticas cotizadas de China. Este acuerdo incluye tres ejes: una inversión financiera por parte de Tasly en Pha


Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), società biofarmaceutica impegnata in un approccio pionieristico allo sviluppo di terapie innovative basate sulla ricombinazione e sul riposizionamento di farmaci già noti, ha oggi annunciato la sigla di un accordo strategico con Tasly Pharmaceutical (Shanghai: 600535), gruppo che figura tra le 10 case farmaceutiche quotate in borsa più importanti della Cina. Il partenariato si fonda su tre assi principali: un investimento finanziario in Pharnext da parte di Tasly, lo sviluppo di una nuova pipeline di combinazioni sinergiche grazie a una piattaforma condivisa e, infine, la concessione della licenza del prodotto di punta di Pharnext per la commercializzazione nel mercato cinese.


PARIJS--(BUSINESS WIRE)--Pharnext SA (Parijs:ALPHA) (FR00111911287 – ALPHA), een biofarmaceutisch bedrijf dat medicijnen innoveert door bestaande geneesmiddelen te combineren of te herpositioneren, heeft vandaag zijn strategische akkoord met Tasly Pharmaceutical (Shangai: 600535) aangekondigd. De bedrijfsgroep staat in de Chinese top 10 van beursgenoteerde farmaceutische bedrijven. De samenwerking voltrekt zich over drie assen: financiële investeringen van Pharnext in Tasly, de ontwikkeling van een nieuwe pijplijn van synergetische combinaties via een gemeenschappelijk platform, en een licentie voor Pharnexts belangrijkste product voor verkoop op de Chinese markt. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.


Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced the signature of a strategic agreement with Tasly Pharmaceutical (Shanghai: 600535), a group ranked amongst China’s top 10 listed pharmaceutical companies. This partnership includes three axes: a financial investment by Tasly in Pharnext; the development of a new pipeline of synergistic combinations through a shared platform; and the license of Pharnext’s lead product for the Chinese market. Pharnext has requested Euronext to resume trading on its stock exchange effective as of Euronext Paris market opening on Wednesday May 10th, 2017 at 9:00am CEST. As a reminder, trading was suspended, as requested by the company and in agreement with the AMF (French Market Authority), on Tuesday May 9th, at 2:30pm (CEST). The above-mentioned major agreement is composed as follows: “This strategic partnership with Tasly is a major milestone: it confirms the global interest in and the value of our innovative technology platform, PLEOTHERAPY™. This partnership will provide access to new markets and new indications for Pharnext technology and products, while also integrating components of modernized traditional Chinese medicine,” said Prof. Daniel Cohen, M.D., Ph.D., Co-Founder and CEO of Pharnext. “We are very pleased and honored to collaborate with Tasly, a visionary company with an impressive history of revolutionizing the use of traditional Chinese medicine in a modernized form.” “We are very pleased to enter into a meaningful collaboration with Pharnext,” said Mr. Yan Kaijing, Chairman of Tasly Pharmaceuticals. “The joint-venture we are creating has the potential to generate a robust pipeline of new therapeutics. This partnership allows us to secure a significant equity interest in Pharnext, as well as the Chinese commercialization rights for their lead asset for Charcot-Marie-Tooth Type 1A disease. We will rely on Tasly's advantages of its existing biomedical R&D platform and access to the Chinese hospital network; as well as Pharnext’s remarkable drug R&D technological know-how to develop high-potential drug combinations, addressing important unmet medical needs. Based on biological disease network pharmacology, this partnership will exploit the immense potential of modernized Chinese traditional medicine, characterizing in a novel and precise way the mechanism of action of each combination we will develop.” Pharnext is an advanced, clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team. The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287). Tasly Pharmaceutical Group Co., Ltd. was listed on Shanghai Stock Exchange in August 2002 (Stock Code 600535). The company concept is "To share the joy of health with all” and the company mission “To improve human life and quality of life”. Tasly is committed to promoting the integration of Traditional Chinese Medicine (TCM) with modern medical and pharmaceutical technologies. It is also committed to building the first international brand of modernized TCM. “To become the global innovation leader of modern TCM and the scientific standard maker of modern TCM” is our target. To achieve this goal, Tasly will strive to bring modernized TCM to international pharmaceutical standards. To support its development strategy of “Comprehensive Internationalization”, Tasly has set up a complete manufacturing chain which respects international guidelines and exploits intelligent manufacturing system. Based on its ”Two Wheel of Innovation and Capitalization” strategy, Tasly has developed several core competitive advantages, such as its R&D model, its multi-level product system, its multi-dimensional patent protection system as well as its commercial and marketing network. The investment of €20 million by Tasly in Pharnext will be in two forms: €5 million in shares, at a price of €12.5 per share, and €15 million in convertible bonds (CB), paid at a rate of approximately 5%, and automatically converted at a price of €13 per share once the price has exceeded this value, on average, for 3 consecutive months. Tasly will also have the opportunity to convert their CB at a price of €13 per share at any time if the price is below this value. In the event of non-conversion at the end of 3 years, the CB would be, at the option of Pharnext, either repaid or converted at the market price with a discount of 20%. For clinical development and commercialization phases, Tasly and Pharnext will benefit from licenses with respect to the following a priori guidelines: These licenses will be granted to Pharnext and / or Tasly on payment to the JV of a share of the platform research costs, and a term repayment on sales or realized income. Tasly will ensure funding of the JV at its inception, with a cash contribution of 70 million RMB (€9.3 million) for new research and at least as much for the development of PXT3003 in the Chinese market. The license to the JV of the drug candidate PXT3003 for Charcot-Marie-Tooth Type 1A disease in the Chinese market will result in an upfront payment by the JV to Pharnext of €2 million. The closing of these 3 agreements is expected to take place around the end of June 2017.


« Ce partenariat stratégique avec Tasly représente une étape majeure : il confirme l’intérêt mondial et la valeur de notre plateforme technologique innovante, PLEOTHERAPY™. Ce partenariat donnera accès à de nouveaux marchés et de nouvelles indications à la technologie et aux produits de Pharnext, tout en y intégrant des composantes de la médecine traditionnelle chinoise modernisée » déclare le Pr. Daniel Cohen, M.D., Ph.D., Co-fondateur et Directeur Général de Pharnext. « Nous sommes très heureux et honorés de collaborer avec Tasly, une société visionnaire, à l’histoire fulgurante qui a révolutionné le recours à la médecine traditionnelle chinoise sous une forme modernisée. » « Nous sommes ravis d’entrer dans une collaboration majeure avec Pharnext » déclare Mr. Yan Kaijing, Président Directeur Général de Tasly Pharmaceuticals. « Cette Joint-Venture que nous créons a le potentiel de générer un portefeuille robuste de nouvelles thérapies. Ce partenariat nous permet de réaliser un investissement significatif dans Pharnext et nous donne les droits de commercialisation sur le marché chinois pour leur produit le plus avancé dans la maladie de Charcot-Marie-Tooth de type 1A. En nous appuyant à la fois sur les avantages de la plateforme R&D de Tasly et de son implantation dense dans le réseau hospitalier chinois ; et sur la remarquable technologie de découverte de médicaments de Pharnext, nous développerons des combinaisons de médicaments à haut potentiel pour répondre aux besoins médicaux non satisfaits. Appuyées sur la pharmacologie des réseaux biologiques des maladies, ce partenariat nous permettra d’exploiter l’immense potentiel des médicaments issus de la médecine traditionnelle chinoise modernisée, grâce à une caractérisation précise et nouvelle du mécanisme d’action de chaque combinaison. » Pharnext est une société biopharmaceutique à un stade avancé de développement fondée par des scientifiques et entrepreneurs de renom, dont le Professeur Daniel Cohen, pionnier de la génomique moderne. Pharnext a deux produits en développement clinique. PXT3003 est en Phase 3 internationale dans la maladie de Charcot-Marie-Tooth de type 1A et bénéficie du statut de médicament orphelin en Europe et aux Etats-Unis. PXT864 a obtenu des résultats de Phase 2 positifs dans la maladie d’Alzheimer. Pharnext est le pionnier d’un nouveau paradigme de découverte de médicaments: PLEOTHERAPY™. La société identifie et développe des combinaisons synergiques de médicaments repositionnés à faible dose. Ces PLEODRUG™ présenteraient de nombreux avantages importants : efficacité, innocuité et propriété intellectuelle solide incluant plusieurs brevets de produit déjà délivrés. Pharnext est soutenue par une équipe scientifique de renommée internationale. Le Groupe Tasly Pharmaceutical Co., Ltd. est coté sur la bourse de Shanghai depuis août 2002 (Shanghai : 600535). Le concept de la société est : « Partager la joie d’être en bonne santé avec tous » et sa mission : « Améliorer la qualité de vie de l’Homme ». Tasly est pleinement engagé à promouvoir l’intégration de la médecine traditionnelle chinoise (TCM) avec les technologies médicales et pharmaceutiques modernes. La société est aussi engagée à construire la première marque internationale de médicament issue de la TCM modernisée. « Devenir le leader mondial de la TCM modernisée et le pionnier des nouvelles normes scientifiques associées à ces produits » est notre objectif. Pour l’atteindre, Tasly mettra tout en œuvre pour élever la TCM modernisée aux normes pharmaceutiques internationales. Pour soutenir sa stratégie de développement à l’international, Tasly a mis en place une chaine de fabrication industrielle complète respectant les directives internationales tout en exploitant un système de fabrication intelligent. S’appuyant sur sa politique d’innovation et de croissance « Two Wheel of Innovation and Capitalization », Tasly a développé plusieurs avantages compétitifs clefs tels que : son modèle de R&D, la spécificité multiple de ses produits, la propriété intellectuelle de ses produits, ainsi que son réseau commercial et marketing. L’investissement de 20 millions d’euros de Tasly dans Pharnext, interviendra sous deux formes : 5 millions d’euros en actions, au prix unitaire de 12,5 euros, et 15 millions d’euros en obligations convertibles (OC), rémunérées à un taux d’environ 5%, et automatiquement converties à un prix de 13 euros par action dès que le cours aura dépassé cette valeur, en moyenne, pendant 3 mois consécutifs. Tasly aura également la possibilité de convertir ses OC à 13 euros à tout moment si le cours est inférieur à ce prix. En cas de non conversion au bout de 3 ans, les OC seraient, à l’option de Pharnext, soit remboursées, soit converties au cours du marché, avec une décote de 20%.


Ling S.,Monash University | Luo R.-Z.,Tasly Pharmaceutical Co | Nheu L.,Monash University | Guo Z.-X.,Tasly Pharmaceutical Co | And 2 more authors.
Journal of Cardiovascular Pharmacology | Year: 2012

T89 (Dantonic) is a modern herbal medicine currently used in Chinese hospitals for the management of ischemic heart disease. This dose-escalation clinical trial aims to assess tolerability of Western people to T89. Healthy Australian adults of non-Asian background orally took a single dosage of 6, 8, 10, 12, 13, 14, 15, or 16 T89 capsules (6 people for each dose) and were assessed with respect to symptoms and physical signs, electrocardiogram, hematology, plasma biochemistry, and urinalysis. Secondary objectives were to determine the dose-limiting toxicity and maximum-tolerated dose. It found that a single dose of T89 up to 16 capsules was not associated with significant adverse events or abnormalities in clinical laboratory tests and electrocardiogram parameters, except minor symptoms reported included mild and transient dizziness, stomach discomfort, diarrhea, and involuntary muscular contraction. The incident rate of these symptoms was generally low (1/30, 3.3%) but increased (7/18, 38.9%) in higher dose (≥14 capsules) groups. No defined dose-limiting toxicity events occurred; so the study could not define the maximum-tolerated dose. In conclusion, a single dose of T89 up to 13 capsules, 4 times of a regular therapeutic dosage, is generally safe and tolerated by individuals of non-Asian background. © 2012 by Lippincott Williams & Wilkins.


PubMed | Henan University, Peking Union Medical College, Nanjing Medical University, Tianjin University and 5 more.
Type: | Journal: Journal of child psychology and psychiatry, and allied disciplines | Year: 2015

Tourette syndrome (TS) is a common tic disorder in children and adolescents. There is preliminary evidence that herbal medicine may possess the potential to treat tics. The purpose of this study was to formally evaluate the efficacy and safety of 5-Ling Granule (5-LGr), a proprietary polyherbal product, for the treatment of patients with TS in comparison with tiapride and placebo.In this multisite, double-blind, double-dummy, randomized, placebo-controlled trial, 603 patients with TS aged 5-18years were randomly assigned to treatment with placebo (n=117), tiapride (n=123, 200-400mg/day) or 5-LGr (n=363, 15-22.5g/day) for 8weeks. The primary outcome was measured using the Yale Global Tic Severity Scale (YGTSS) and its subscales, total tic Score (TTS) and tic-related impairment. Incidence of adverse events was compared among the three groups.While tics of all patients were reduced over time, 5-LGr and tiapride treatment produced significantly greater improvement on the YGTSS overall scale and subscale for TTS and impairment at endpoint than the placebo. Seventy-four percentage of patients in the 5-LGr arm and 68.3% in the tiapride arm had clinical response and these rates of response were significantly higher than those on placebo (44.0%, p<.001). The incidence of overall adverse events was significantly fewer for patients on placebo and 5-LGr compared to tiapride (11.2% and 13.8% vs. 26.0%, p=.002); in particular physical tiredness, dizziness and sleep disturbance.The clinical efficacy of 5-LGr is comparable to tiapride in reducing tics. Its safety profile is better than tiapride. 5-LGr can be considered a safe and effective therapy for TS (Trial registration: www.clinicaltrials.gov: NCT01501695).


PubMed | Chinese Academy of Sciences, Jiangsu Province Hospital of Traditional Chinese Medicine, Tasly Pharmaceutical Co., University of Chicago and 6 more.
Type: | Journal: Journal of ethnopharmacology | Year: 2015

Salvia miltiorrhiza (Danshen in Chinese) is a common traditional Chinese herbal medicine often used to treat many medical conditions. The Compound Danshen Dripping Pill (CDDP) is a danshen-containing Chinese herbal product for the treatment of cardiovascular diseases. However, to date, no controlled clinical studies have been conducted to evaluate the effects of CDDP on diabetic retinopathy (DR).The present large-scale clinical trial was designed to assess the effectiveness and safety of CDDP in treating patients with non-proliferative diabetic retinopathy (NPDR).223 NPDR patients were enrolled in this controlled trial. Subjects received oral study medications three times daily for 24 weeks. The four groups were placebo, low-dose (270 mg), mid-dose (540 mg) and high dose (810 mg herbal medicine). Primary endpoints were changes in fluorescence fundus angiography (FFA) and fundoscopic examination parameters.At 24 weeks, for the FFA, the percent of Excellent and Effective in the high-dose and mid-dose CDDP groups was 74% and 77%, respectively, very significantly higher than 28% in the placebo group (P<0.001). For fundoscopic examination, the percent of Excellent and Effective in the high-dose and mid-dose CDDP groups was 42% and 59%, respectively, very significantly higher than 11% in the placebo group (P<0.001). No adverse events with clinical significance were observed.DR is a severe microvascular complication of diabetes and a major cause of adult blindness worldwide. Our clinical trial data demonstrated the therapeutic value and safety of a danshen-containing Chinese herbal medicine in patients with diabetic retinopathy.


Tong X.L.,Chinese Academy of Sciences | Wu S.T.,Tianjin University of Traditional Chinese Medicine | Lian F.M.,Chinese Academy of Sciences | Zhao M.,Tasly Pharmaceutical Co. | And 10 more authors.
Diabetes, Obesity and Metabolism | Year: 2013

Aim: TM81 (or Tang-Min-Ling-Wan) is a Chinese medicine. Previous studies suggested that this medicine is effective for treating type 2 diabetes. This controlled trial evaluated the safety and effectiveness of TM81 in the treatment of type 2 diabetic patients. Methods: This study was a large-scale controlled clinical trial to evaluate the safety and effectiveness of TM81 on type 2 diabetes. After a 2-week run-in period, 480 overweight type 2 early-stage diabetic patients [35-65years old, HbA1c ≥ 7.0%, fasting plasma glucose (FPG) 7.0-13.9mM or 2h plasma glucose (PG)>11.1mM, body mass index (BMI)≥24kg/m2] were enrolled. These patients were divided into a TM81 group and placebo group in a 3:1 ratio. The subjects received 6g TM81 or placebo, three times daily for 12weeks. Results: After treatment, the HbA1c decrease was 1.02% in the TM81 group versus 0.47% in the placebo group. The FPG decreased 0.8±0.1 mM in the TM81 group versus an increase of 0.2±0.2mM in the placebo group. The PG decreased 2.7±0.3 mM in the TM81 group versus a decrease of 0.9±0.4 mM in the placebo group (all p<0.05). The TM81 was more effective for patients with higher baseline HbA1c levels. The TM81 group also showed improved β-cell function and increased homeostatic model assessment (HOMA)-β. In addition, body weight, BMI and waist circumference of subjects in the TM81 group were reduced, and the symptoms related to diabetes were improved. There were no significant differences in the types and frequency of adverse reactions between the two groups. Conclusions: The data showed that TM81 is effective in controlling blood glucose level and is safe to use in patients with early-stage type 2 diabetes. © 2012 Blackwell Publishing Ltd.

Loading Tasly Pharmaceutical Co. collaborators
Loading Tasly Pharmaceutical Co. collaborators